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Abstract
The fate of orally inhaled drugs is determined by pulmonary pharmacokinetic processes such as parti-
cle deposition, pulmonary drug dissolution, and mucociliary clearance. Even though each single process
has been systematically investigated, a quantitative understanding on the interaction of processes remains
limited and therefore identifying optimal drug and formulation characteristics for orally inhaled drugs
is still challenging. To investigate this complex interplay, the pulmonary processes can be integrated
into mathematical models. However, existing modeling attempts considerably simplify these processes
or are not systematically evaluated against (clinical) data. In this work, we developed a mathematical
framework based on physiologically-structured population equations to integrate all relevant pulmonary
processes mechanistically. A tailored numerical resolution strategy was chosen and the mechanistic model
was evaluated systematically against data from different clinical studies. Without adapting the mech-
anistic model or estimating kinetic parameters based on individual study data, the developed model
was able to predict simultaneously (i) lung retention profiles of inhaled insoluble particles, (ii) particle
size-dependent pharmacokinetics of inhaled monodisperse particles, (iii) pharmacokinetic differences be-
tween inhaled fluticasone propionate and budesonide, as well as (iv) pharmacokinetic differences between
healthy volunteers and asthmatic patients. Finally, to identify the most impactful optimization criteria
for orally inhaled drugs, the developed mechanistic model was applied to investigate the impact of input
parameters on both the pulmonary and systemic exposure. Interestingly, the solubility of the inhaled
drug did not have any relevant impact on the local and systemic pharmacokinetics. Instead, the pul-
monary dissolution rate, the particle size, the tissue affinity, and the systemic clearance were the most
impactful potential optimization parameters. In the future, the developed prediction framework should
be considered a powerful tool for identifying optimal drug and formulation characteristics.
Introduction
Oral drug inhalation can result in high pulmonary drug exposure while maintaining low systemic exposure.
Compared to other routes of administration, this can provide higher local pulmonary efficacy, while simul-
taneously reducing systemic adverse effects (“lung selectivity”) [1, 2, 3]. Therefore, orally inhaled drugs are
considered first-line therapy (amongst other treatment options) to treat respiratory diseases such as asthma
bronchial or chronic obstructive pulmonary disease [4, 5].
While qualitatively, the pharmacodynamic (PD) selectivity for the lung was previously investigated, a
sound quantitative understanding about the pulmonary pharmacokinetics (PK) is still lacking. Specific
pulmonary PK processes after oral drug inhalation were studied in detail, such as the pulmonary particle
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deposition [6, 7, 8] or mucociliary clearance [9, 10]. For example, it is well understood that the central airway
deposition increases with an increasing aerodynamic particle size [7] and that the mucociliary clearance
depends on the localization in the airways [10]. Hence, the impact of mucociliary clearance strongly depends
on particle deposition patterns. However, in contrast to investigations related to the individual processes, the
interplay of the many pulmonary PK processes has received less attention. A comprehensive quantitative
understanding of how these processes contribute to pulmonary and systemic PK, and therefore to lung
selectivity after drug inhalation, is often still lacking [11, 12, 13, 14]. Thus, identifying drug and formulation
characteristics for orally inhaled drugs that maximize lung selectivity as well as long-lasting pulmonary
efficacy is still challenging.
To gain a better understanding on the interplay of pulmonary PK processes, mechanistic modeling
approaches can be applied. However, previous modeling approaches either reduced the given complexity
or lack adequate model evaluation. For example, the mucociliary clearance was described as a first-order
process [15, 16]. Other published population PK models did not differentiate between undissolved and
dissolved drug and consider pulmonary drug absorption as a “one-way process”, i.e. back flow of drug to
the lungs from the systemic disposition is not considered [17, 18, 19]. One mechanistic partial differential
equation (PDE)-based model is available, which included all relevant pulmonary PK processes [20]. This
model, however, was not evaluated against clinical data. Hence, to our knowledge no fully mechanistic
model, with an adequate model evaluation based on clinical and in vitro data, is available. Consequently,
there is currently no adequate framework to quantitatively identify the most impactful drug and formulation
characteristics to achieve good lung selectivity.
In this work, we aimed at developing such a mechanistic pulmonary PK model to capture the complexity
of all relevant pulmonary PK processes (compare Fig 1) and to determine which parameters are the most
suitable optimization criteria to achieve optimal lung selectivity. The biggest mathematical challenge related
to such a model is to adequately describe the joint effect of location-dependent nonlinear mucociliary clear-
ance and particle size-dependent dissolution. To achieve this, a size- and location-structured PDE model
was developed. The resulting PDE model was extensively evaluated, in particular based on clinical PK
data for both budesonide and fluticasone propionate, as these inhaled drugs represent the clinically most
studied compounds. Finally, a sensitivity analysis was performed to determine the most impactful drug and
formulation characteristics and therefore potential optimization parameters to achieve a high lung selectivity.
Models
The mathematical model is introduced in a stepwise manner. First, the (sub)models describing the considered
pulmonary PK processes are given. Next, the full PDE model it presented. The model parametrization is
described in the Results section. Full details concerning derivations, numerical resolution, and additional
model evaluations are given in S1 Appendix, as referenced below.
Modeling of pharmacokinetic processes in the lung
Pulmonary particle deposition
Since orally inhaled drugs are deposited in the lungs within a single breath, pulmonary drug deposition was
considered as an instantaneous rather than a time-dependent process. Pulmonary particle deposition was
simulated with the MPPD software [21] according to the study design of each investigated study (i.e., for
monodisperse particle size formulations as well as the specific particle size distributions of the Diskus R©and
Turbohaler R©devices, respectively [22]). To simulate deposition patterns for asthmatic patients, who are
characterized by a more central deposition compared to healthy volunteers [23, 24], we corrected the depo-
sition patterns in healthy volunteers based on scintigraphy data reported in [25]. A full account of input
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Figure 1: Overview of relevant pulmonary pharmacokinetic processes for orally inhaled drugs.
Adapted and modified from [2].
parameters to predict the deposition patterns and the adaption for asthmatic patients is provided in S1
Appendix(Section 4).
These predictions generated aerodynamic particle size- and lung generation-resolved deposition patterns.
The aerodynamic particle size (the size of a water particle experiencing the same aerodynamic forces as the
considered particle) determines the deposition characteristics of the inhaled particles [26]. In contrast, the
real (geometric) size of an inhaled particle is relevant for dissolution processes [27]. To convert aerodynamic
to geometric particle sizes, which is more relevant for dissolution characteristics, we assumed a spherical
shape of particles and considered the relationship
dgeom = daero
√
ρwater
ρsubstance
,
where daero and dgeom are aerodynamic and geometric particle diameters, respectively; ρwater and ρsubstance
denote density of water and the considered inhaled substance, respectively [28].
In a post-processing step, the (geometric) particle size- and lung generation-resolved deposition patterns
were projected onto the computational grid, ensuring conservation of the number of molecules (full details
are given in S1 Appendix, Section 2.5.1).
Mucociliary clearance
The mucociliary clearance process was parameterized based on a model for mucociliary clearance published
by Hofmann and Sturm (see S1 Appendix, Section 1.2 for details) [10]. In agreement with clinical data,
mucociliary clearance of undissolved particles only depends on the particle location, not on (geometric)
particle size [26]:
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λmc(x) = 0.8791
cm
min
·
(
rbr(x)
1 cm
)2.808
,
where rbr(x) represents the radius of the conducting airways at location x.
Pulmonary drug dissolution
The dissolution of particles in the pulmonary lining fluids was based on an adapted version of the Noyes-
Whitney equation [27]:
d(s, Cflu) =
4pi kdiss
( 43pi)
1/3 ρ
·
(
1− Cflu
Cs
)
· s1/3,
where s denotes the particle volume, ρ the particle density, Cs the saturation solubility, kdiss = D · Cs the
maximum dissolution rate (D= diffusivity), and Cflu the local concentration of dissolved drug in the lining
fluid. A derivation of this equation from the Noyes-Whitney equation, assuming spherical particle geometry,
is provided in S1 Appendix, Section 1.1. To represent the difference in fluid composition between conducting
airways and the alveolar space, in particular in terms of fluid viscosity, different dissolution rate constants
(kbrdiss/k
alv
diss) were assumed in these two regions, leading to dissolution models d
br and dalv, respectively.
Absorption into the lung tissues
After drug dissolution in the pulmonary lining fluids, the drug is absorbed through the airway epithelia into
the lung tissue of the respective airway generation or the alveolar space. Based on reported negligible to
tenfold lower albumin concentrations in epithelial ling fluids in the lung compared to plasma [29, 30, 31],
the absorption rate is calculated assuming no drug binding in the lung lining fluids:
ka = Papp · SA ·
(
Cflu − Ctis
Kpu,tis
)
,
where ka denotes the absorption rate, Papp the effective permeability, SA the airway surface area, and Kpu,tis
describes the lung-to-unbound plasma partition coefficient.
Systemic disposition
The systemic disposition models for both budesonide and fluticasone propionate were based on available
literature information after intravenous administration and oral administration (to include the oral bioavail-
ability of swallowed drug). In contrast to many less mechanistic PK models, the backflow of drug from the
systemic circulation into the lung was mechanistically included in the PDE-based PK model.
Partial differential equation model for orally inhaled drugs
Model equations
To mechanistically combine the considered pulmonary processes in the lung (lung deposition, mucociliary
clearance, pulmonary dissolution, pulmonary absorption to the lung tissue and distribution between lung
tissue and plasma), we adopted the framework of physiologically structured population models (PSPMs)
[32]. In this class of PDE models, the time evolution of a density is described over a state space through a
set of processes that modify the state.
To describe the fate of undissolved particles deposited in the lung, we considered (i) a PSPM with size
and location structure in the conducting airways and (ii) a PSPM with size structure in the alveolar space.
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In these models, size s represents the geometric volume of particles, and location x (length unit) the position
along all conducting airways, between trachea and terminal bronchioles. The state (x, s) of a particle is
changed by mucociliary clearance (impacts on x) and pulmonary dissolution (impacts on s).
The PSPMs were coupled to differential equations describing the PK of dissolved drug molecules in lung
lining fluids and lung tissues (similar to [33]) and published systemic disposition kinetics [15]. The full set of
equations is stated below, a simplified outline of the underlying geometry is provided in Fig 2 and a a detailed
derivation of the full model from the separate PK processes is given in S1 Appendix (Sections 1.3-1.5).
For ease of legibility, the following abbreviations are used as sub-/superscripts in the equations: br
(bronchial, i.e., conducting airways), alv (alveolar space), sys (systemic), sol (solid, i.e., undissolved), flu
(fluid, i.e., dissolved), tis (lung tissue), ctr (central), per (peripheral), mc (mucociliary clearance).
The size- and location-structured PSPM for the density of inhaled particles in suspension in the conduct-
ing airways reads
∂tρ
br(t, x, s) + ∂x
[
λmc(x)ρ
br(t, x, s)
]− ∂s[dbr(s, Cbrflu(t, x))ρbr(t, x, s)] = 0
ρbr(0, x, s) = ρbr0 (x, s) (see S1 Appendix, Sections 2.5.1 and 4)
assuming zero inflow boundary conditions (i.e., no additional source of drug in the conducting airways after
dosing). This PDE was complemented by differential equations for the concentration of dissolved drug in
lining fluids and lung tissue at a particular airway location x:
abrflu(x)∂tC
br
flu(t, x) =
smax∫
0
dbr(s, Cbrflu(t, x))ρ
br(t, x, s)ds
︸ ︷︷ ︸
dissolution
− 2pirbr(x)Papp
(
Cbrflu(t, x)−
Cbrtis(t, x)
Kpu,tis
)
︸ ︷︷ ︸
tissue uptake
abrtis(x)∂tC
br
tis(t, x) = 2pir
br(x)Papp
(
Cbrflu(t, x)−
Cbrtis(t, x)
Kpu,tis
)
− qbr(x)
(
BPCbrtis(t, x)
Kp,tis
− Csysctr (t)
)
︸ ︷︷ ︸
systemic uptake
both with zero initial conditions.
In the alveolar space, the size-structured PSPM for the density of inhaled particles in suspension reads
∂tρ
alv(t, s)− ∂s
[
dalv(s, Calvflu (t))ρ
alv(t, s)
]
= 0
ρalv(0, s) = ρalv0 (s) (see S1 Appendix, Sections 2.5.1 and 4)
Again, zero inflow boundary conditions were assumed (no additional source of drug in the alveolar space
after dosing) the and the PDE is complemented by differential equations for the concentration of dissolved
drug in alveolar lining fluids and alveolar lung tissue:
V alvflu
dCalvflu
dt
(t) =
smax∫
0
dalv(s, Calvflu (t))ρ
alv(t, s)ds− Papp SAalv
(
Calvflu (t)−
Calvtis (t)
Kpu,tis
)
V alvtis
dCalvtis
dt
(t) = Papp SA
alv
(
Calvflu (t)−
Calvtis (t)
Kpu,tis
)
−Qalv
(
BPCalvtis (t)
Kp,tis
− Csysctr (t)
)
with zero initial conditions.
The equations describing the PK in the conducting airways and the alveolar space are coupled through
5
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gen. 3
…
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(trachea)
Mucociliary
clearance
Dissolution
rbr(x)
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Figure 2: Geometry of and key processes in conducting airways represented in the mathematical
model. A representative airway (dark grey) is considered in the mathematical model. At each location x
(distance from throat) within this airway, we consider a cylindrical lung model, consisting of concentric
layers of airway (with radius rbr(x)), lung lining fluid (with cross-sectional area abrflu(x)), and lung tissue
(with cross-sectional area abrtis(x)), respectively. Each drug particle (green) is characterized by its location
and size. Over time, particles are moved upwards by mucociliary clearance (yellow) and dissolve into the
airway lining fluid (black arrows).
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the systemic circulation:
Vctr
dCsysctr
dt
(t) =
xTB∫
0
qbr(x)
(
BPCbrtis(t, x)
Kp,tis
− Csysctr (t)
)
dx
︸ ︷︷ ︸
exchange with conducting airways
+Qalv
(
BPCalvtis (t)
Kp,tis
− Csysctr (t)
)
︸ ︷︷ ︸
exchange with alveolar space
−Qsys(Csysctr (t)− Csysper(t))− CL · Csysctr (t)
Vper
dCsysper
dt
(t) = Qsys
(
Csysctr (t)− Csysper(t)
)
The following expressions appear in these equations:
• x is the location within a prototypical airway, varying from 0 (trachea, corresponding to airway gener-
ation 1) to xTB (terminal bronchioles, corresponding to airway generation 16).
• s is the geometric particle volume, varying between 0 and smax (device- and formulation-specific max-
imum particle size deposited)
• ρbr/ρalv are the PSPM densities, with units number of particlesmL · cm and number of particlesmL , respectively
• Cyz is the concentrations of dissolved drug in lining fluid (z = flu) or lung tissue (z = tis) in a particular
location of the conducting airways (y = br) or in the alveolar space (y = alv)
• dbr / dalv are the dissolution rates in conducting airways / alveolar space, depending on particle size
s and concentration of already dissolved drug
• λmc is the mucociliary clearance in the conducting airways, assumed to depend only on location x, not
on (geometric) particle size s.
• Papp is the apparent permeability of the drug
• SAalv is the surface area of the alveolar space
• rbr(x) is the airway radius (including lining fluid) at location x (see Fig 2)
• Kp,tis / Kpu,tis are the lung-to-plasma and lung-to-unbound plasma partition coefficients, respectively
• BP is the blood-to-plasma ratio of the drug
• abrflu(x) / abrtis(x) is the cross-sectional area of lung lining fluid / lung tissue at location x within the
conducting airways
• qbr(x) is the location-resolved blood flow (see section Model parametrization below)
Numerical resolution
To solve the mathematical model numerically, we employed an upwind discretization of the PSPMs [34]
together with an implicit discretization of all linear processes (MCC, absorption, systemic processes) [35, 36].
The fluxes across PDEs (mucociliary elevator and dissolved / absorbed drug) were discretized ensuring
that all conservation laws were fulfilled at the discrete level. The discretized model and all analyses were
implemented in MATLAB R2018b [37]. A full description of the discretization scheme is given in S1 Appendix
(Section 2) and the MATLAB implementation is provided as S1 File.
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Results
Key findings from literature review
As a first step, PK studies for both budesonide and fluticasone propionate were identified. These drugs were
selected as they represent the most studied inhaled drugs for which the interplay between pulmonary deposi-
tion, pulmonary dissolution, mucociliary clearance, as well as pulmonary absorption has been systematically
discussed [2, 24]. In total, ten different clinical PK studies on these drugs were identified (see S1 Table).
After reviewing all PK studies, we identified two important aspects. First, the area under the curve
reported by Usmani et al. [38] could not be reproduced considering the systemic clearance for fluticasone
propionate reported by Mackie et al. [39]. Even in the most extreme and certainly unrealistic assumptions,
namely with 100% of inhaled drug particles deposited in the lungs and no mucociliary clearance, the systemic
AUC would still be at least 25% lower than reported (see calculation in S1 Appendix, Section 3.3).
Second, there is a considerable between-study variability in reported (dose-normalized) systemic drug ex-
posure (same drug, comparable dose, comparable patient population, same inhalation device). For example,
both Mo¨llmann et al. [40] and Harrison and Tattersfield [41] investigated the systemic PK after budesonide
inhalation with the Turbohaler R©for slightly different doses of 1000 µg, and 1200 µg. The reported dose-
normalized Cmax and AUC0-Inf values varied by more than twofold. In contrast, the relative shape of the PK
profiles, which are not dependent on the absolute plasma concentrations, were in good agreement between
both studies. A full summary of exposure metrics is given in S1 Table.
Based on these findings, we decided that predicting the absolute plasma concentrations of one single
selected PK study is not meaningful or could even result in a selection bias. Instead, PK studies with multiple
study arms, which allow for a direct within-study comparison of different PK profiles, were considered (i.e.,
studies with only a single investigated drug, a single inhaled particle size and a single investigated population
were not included). A short overview of the reviewed PK studies, including a comment on why specific studies
were considered, can be found in S1 Table. In summary, the selected PK studies comprised the following
aspects relevant for model building and model evaluation: (i) the lung retention profiles for insoluble particles
[26], (ii) the impact of different particle sizes on the systemic PK [38], (iii) different systemic PK profiles
after inhalation of either budesonide or fluticasone propionate [40, 41], and (iv) different systemic PK profiles
between healthy volunteers and asthmatic patients [41].
Model parametrization
The PDE-based model was not adapted to individual studies, i.e., no (pharmacokinetic) parameters were
estimated based on the studies which were used for model evaluation. Instead, the pulmonary part of the PDE
model was fully parametrized based on physiological and drug-specific in vitro data (a priori predictions).
Both pulmonary drug deposition and mucociliary clearance were considered as drug-independent generic
processes based on particle size and airway characteristics alone, not requiring any drug-specific parameters.
Drug-specific parameters, such as the maximum dissolution rate (kdiss), as well as drug solubility in pul-
monary lining fluids were either based on literature information or in-house data on in vitro dissolution and
solubility. No direct comparison between alveolar and mucus dissolution kinetics could be retrieved from
literature or in-house data. Therefore, a 5-fold decrease of kdiss in the conducting airways compared to the
alveolar space was assumed for all model-based simulations. A comprehensive list of parameter values is
given in Table 1 (physiological parameters) and Table 2 (drug-specific parameters).
To achieve a location-resolved parametrization of the conducting airways, we used generation-specific
anatomical data of the conducting airways from [53], namely the length l(g) and radius r(g) of each airway
generation g. From these values, location-resolved blood flows and cross-sectional lining fluid and lung tissue
areas were calculated by assuming the following:
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Table 1: Physiological parameters.
Parameter Symbol(s) Value
Perfusion of conducting airways Qbr 7.8 L/h #1
Perfusion of alveolar space Qalv 312 L/h #2
Bronchial tissue volume V brtis 144 mL
#3
Alveolar tissue volume V alvtis 388 mL
#3
Alveolar fluid volume V alvflu 36 mL [42]
Alveolar surface area SAalvflu 130 m
2 [43]
Location-resolved parameters rbr, abrflu, a
br
tis,q
br see main text
#1 calculated based on 2.5 % of cardiac output [44]
#2 equal to cardiac output, taken from [45, Table 22]
#3 computed from lung tissue weight of 532 g [45], assuming a tissue
density of 1 g/mL and 27 % central/73 % peripheral lung tissue
weight fraction as in [33, Supplement].
Summary of physiological parameters obtained from literature.
Table 2: Drug-specific parameters.
Parameter Symbol Fluticasone propionate Budesonide
Central volume of distribution Vctr 31 L [15] 100 L [15]
Peripheral volume of distribution Vper 613 L [15] 153 L [15]
Clearance CL 73 L/h [15] 85 L/h [15]
Intercompartmental clearance Qsys 55.2 L/h [15] 1701 L/h [15]
Oral bioavailability (of swallowed drug) Foral 0 % [15] 11 % [15]
Absorption rate constant from GI tract ka – 0.45 1/h [15]
Fraction unbound in plasma fu,plasma 1.16 %
#1 16.1 %#1
Lung:plasma partition coefficient Kp,tis 2.47
#2 8 [46]
Permeability Papp 92.6 · 10−6 cm/s#1 5.33 · 10−6 cm/s[47]
Blood:plasma ratio BP 1.83#1 0.8 [48, 49]
Molecular weight MW 500.57 430.53
Density ρ 1.43 mol/L 3.02 mol/L
Solubility Cs 12.0 µM
#1 69.8 µM#1
Maximum dissolution rate kalvdiss 6.17 · 10−5 nmolcm·min #3 3.3 · 10−4 nmolcm·min #3
Inhalation device-specific parameters see S1 Appendix, Section 4
#1 in-house data: fraction unbound was determined with an in vitro binding assay as described in [50],
permeability was determined based on an in vitro permeability assay with Calu cells, with assay con-
ditions as described for MDCK II cells in [50]. The in vitro assay setup for determining Blood:Plasma
ratio and drug solubility in surfactant-containing media is described in S1 Appendix, Section 5.
#2 calculated based on fu,plasma (in-house data) and rat lung slice binding [51]
#3 determined from in vitro dissolution data from [52] (see S1 Appendix, Section 3.1 for full details).
For both drugs, two-compartment systemic PK models proposed in the literature were used.
• Using length of airway generations, we determined a continuous representation rbr(x) of the airway
radius by linear interpolation between airway centerpoints.
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• We assessed literature data on lining fluid height hbrflu(x) for different airway generations and found
an appropriate linear location-to-height of lining fluid-relationship (see S1 Appendix, Section 3.2, for
details). Using the cylindrical geometry assumption depicted in Fig 2B, abrflu(x) could be determined
from hbrflu(x) and the airway radius r
br(x) via
abrflu(x) = pi
(
rbr(x)2 − (rbr(x)− hbrflu(x))2).
• We assumed the cross-sectional area of conducting airway tissue abrtis(x) to be proportional to cross-
sectional lining fluid area abrflu(x), with proportionality constant determined by the known total tissue
volume of the central lung V brtis , i.e., via the relation
∫ xTB
0
abrtis(x)dx = V
br
tis .
• We assumed a homogeneous perfusion of drug tissue within the conducting airway tissue, i.e., a location-
resolved blood flow qbr(x) proportional to abrtis(x) and matching the total blood flow in the central lung
Qbr, i.e. such that
∫ xTB
0
qbr(x)dx = Qbr.
We emphasize that the pulmonary PDE model was fully parametrized based on in vitro and physiological
data, not fitted to the clinical data described in section Model evaluation below. A single adaptation was
done based on physiological reasoning since no quantitative literature information could be retrieved, namely
a 5-fold decrease of dissolution rate in the conducting airways compared to the alveolar space. The reason
for this adapted dissolution rate constants is that the epithelial lining fluid in the conducting airways –the
mucus– contains a lower concentration of surfactants (which facilitate dissolution), compared to the alveolar
lining fluid. In addition, the upper layer of the mucus is characterized by a high viscosity, which can also
lead to a slower dissolution in comparison to the alveolar space.
Model evaluation
The mathematical model was evaluated in a stepwise approach. The first evaluation of the PDE-based
inhalation PK model was based on a simulation of inhaled gold / polystyrene particles. As these particles
do not dissolve in the pulmonary lining fluids, the interplay of deposition and mucociliary clearance can be
evaluated independent of other pulmonary PK processes such as pulmonary dissolution or drug absorption.
The initial particle retention was well described with 47% of the deposited particles retained over 8 h and
26% retained over 24 h (Fig 3, left). However, the retention after 48 h was underpredicted, i.e. the data
indicated a fraction of 7–36% not being cleared from the lung, whereas the simulation indicated less than
5% retention (Fig 3, right).
After evaluating the interplay of pulmonary deposition and mucociliary clearance, the pulmonary disso-
lution process was evaluated based on data from inhaled monodisperse drug formulations. In this evaluation
step, the systemic PK of 1.5, 3, and 6 µm-sized particles (aerodynamic diameter) were simulated for the
slowly dissolving inhaled drug fluticasone propionate. Simulation results were compared to the determined
AUC0-12h, Cmax, and Tmax published by Usmani et al. As explained above, the absolute exposure metrics
stated in the publication could not be reproduced. Rather than through goodness of prediction of absolute
exposure measures, we therefore evaluated the model by comparing the relative change of exposure metrics
across the three considered particle sizes. Of the model-predicted exposure metrics AUC0-12h and Cmax,
67% were within 2-fold and 83% within 3-fold of the reported ratios (compare Table 3). The predicted
1.5 µm : 3 µm Tmax ratio matched the experimental data well, however the other predicted Tmax ratios
showed larger discrepancies due to a predicted very flat concentration-time profile for 6 µm particles.
As a last step of the PDE model evaluation, systemic PK profiles of fluticasone propionate and budesonide
were simulated for both healthy volunteers and asthmatic patients, the only assumed difference between both
populations being a more central particle deposition in asthma patients (see deposition profiles in S2 Fig).
For fluticasone propionate inhaled by healthy volunteers with the Diskus R©device, a Cmax of 0.38 nM per
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Figure 3: Pulmonary retention profiles of inhaled insoluble particles. Pulmonary retention of
inhaled monodisperse 5 µm-sized (aerodynamic diameter) gold and polystyrene (PSL) particles. The amount
retained is described as a fraction of the initially deposited lung dose. Left: retention-time profile over 24 h,
right: retention-time profile over 10 days. Data points: digitized data from six subjects from [26]; solid line:
model-based predictions of lung retention.
Table 3: Evaluation of model predictions for different particle
sizes.
Exposure AUC0-12h Cmax Tmax
metric ratio Data Model Data Model Data Model
1.5 µm : 3 µm 1.04 1.65 1.52 4.23 0.40 0.52
1.5 µm : 6 µm 4.16 4.92 5.00 20.7 0.26 0.09#1
3 µm : 6 µm 4.01 2.98 3.27 4.90 0.63 0.17#1
#1 For 6 µm particles, the predicted concentration-time profile was very
flat, resulting in a late Tmax and therefore low 1.5 µm : 6 µm and
3 µm : 6 µm Tmax ratios.
Comparison of model-predicted and reported PK between three different inhaled monodisperse particle
formulations of fluticasone propionate, with aerodynamic diameters of 1.5, 3, and 6 µm, respectively [25].
Due to uncertainty in reported absolute PK parameter readouts, the ratios between both listed particle
sizes are reported instead. For example, the 1.5 µm-sized particles yielded a 4.16 fold higher measured
AUC0-12h in comparison to the 6 µm-sized particles, whereas the model-based prediction resulted in 4.92
fold higher AUC0-12h.
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mg dose, an AUC0-12h of 1.8 nM·h per mg dose, and a Tmax after 41 min were predicted. For budesonide
(Turbohaler R©), dissolution as well as absorption to the systemic circulation were predicted to be faster
compared to fluticasone propionate, with a Cmax of 2.2 nM per mg dose; Tmax was similar and AUC0-12h
larger (10 nM ·h per mg dose). The comparison of model-predicted PK profiles for fluticasone propionate
and budesonide in comparison to observed clinical data from healthy volunteers [40, 41] are displayed in
Fig 4. For fluticasone propionate, the dose-normalized data from literature were in agreement, and the
simulation results closely matched these data. For budesonide, there was a between-study, but not within-
study discrepancy between reported dose-normalized concentration-time profiles; model predictions were
well within the reported range. The discrepancy in the data was not explainable by dose-nonlinear PK,
since a 2.5-fold dose change in [40] did not impact on the normalized profiles. Of note, the model-predicted
dose-normalized concentration-time profiles based on these scenarios all overlapped, which agrees with the
clinically observed absence of dose-dependent pharmacokinetics in plasma for both fluticasone propionate
and budesonide.
Systemic PK after single dose inhalation (healthy volunteers)
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Figure 4: Pharmacokinetics after drug inhalation of clinical formulations. Plasma concentration-
time profiles after drug inhalation of fluticasone propionate inhaled with the Diskus R©inhalation device (left
panel) and budesonide inhaled with the Turbohaler R©inhalation device (right panel). Data points: digitalized
raw data from [40, 41], solid lines: PDE-model based predictions for 200, 500, and 1000 µg doses of fluticasone
propionate and 400, 1000, and 1200 µg doses for budesonide (due to an almost dose-linear PK, model
predictions overlap).
The same simulations for asthmatic patients resulted in lower systemic exposure. For fluticasone propi-
onate, 28% of the initially deposited lung dose was predicted to be eliminated via mucociliary clearance in
healthy volunteers, compared to 53% in asthmatic patients due to the more central particle deposition. For
budesonide, 6% and 29% of the initially deposited lung dose were predicted to be eliminated via mucociliary
clearance in healthy volunteers and asthmatic patients, respectively. A comparison of model-predicted and
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clinically observed differences between healthy volunteers and asthmatic patients is given in Table 4. For
fluticasone propionate, simulations were in good agreement with clinical data, whereas for budesonide, the
effect of the disease was overpredicted. However, the model-predicted stronger disease effect for fluticasone
propionate compared to budesonide –in terms of an AUC increase– was in agreement with the clinical data.
Table 4: Evaluation of model-predicted PK differences between healthy
volunteers and asthmatic patients.
Healthy:asthmatic AUC0-12h Cmax Tmax
ratio for substance Data Model Data Model Data Model
Fluticasone propionate 1.76 1.64 1.67 1.48 1 1.05
Budesonide 0.88 1.43 1.07 1.51 NA#1 1.05
#1 since the reported Tmax values both corresponded to the first observed time
point, no meaningful statement about Tmax ratios can be made.
Comparison of model-based and literature-reported PK difference between healthy volunteers and
asthmatic patients. Data are taken from [41] (1000 µg fluticasone propionate with Diskus R©/ 1200 µg
budesonide with Turbohaler R©). Ratios larger than 1 indicate higher values in healthy volunteers, whereas
ratios smaller than 1 indicate higher values in asthmatic patients. NA, not available.
Sensitivity analysis
As a last step of the analysis, a sensitivity analysis was applied to the evaluated PDE model to determine
the most impactful parameters (among formulation-dependent, physiological, and drug-specific parameters)
on the following PK readouts:
(i) AUC0-24h in conducting airway tissue,
(ii) the average concentration in the conducting airway tissues after 24 h (which is supposed to correlate
with long-lasting efficacy of an inhaled drug), and
(iii) lung selectivity, which is expressed as a ratio between the pulmonary AUC (in conducting airways)
and the systemic AUC.
This last quantity is supposed to provide a metric of local efficacy weighed against systemic safety, which is
an important optimization criterion for inhaled drugs. As the relevance of an input parameter can depend
on the complete set of the initial input parameters, the sensitivity analysis was performed starting with the
parameters for (i) a 250 µg fluticasone propionate dose (see Fig. 5) and (ii) a 800 µg budesonide dose (see
S1 Fig), both representing approved doses [54, 55].
Overall, the order of impactful parameters only differed marginally for the different exposure metrics
and different drugs. A more than 50% change was observed for tissue volume, tissue partition coefficient,
perfusion, dissolution rate and systemic clearance. Particle size had a considerable impact for fluticasone
propionate, and less for budesonide. For fluticasone propionate, the impact of drug solubility in the airway
lining fluids was negligible, whereas for budesonide, although being the more soluble drug, a relevant impact
was predicted since lining fluid concentrations approached the solubility (see S3 Fig). Other parameters, such
as lining fluid volume and all physiological parameters related to the alveolar space were characterized by
negligible impact on the exposure metrics. The impact of deviating the model parameters by a 2-fold increase
and 2-fold decrease was typically antithetical. As a notable exception, the dissolution rate in the conducting
airways resulted in lower lung tissue concentration after 24 h, regardless of whether the dissolution rate was
increased or decreased 2-fold.
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Figure 5: Results of the performed sensitivity analysis for fluticasone propionate. For each of
three different exposure measures readouts (AUC, C24, and lung selectivity), the impact of a 2-fold increase
(blue) and decrease (red) are depicted for a the formulation parameter particle size (top bar) and a set of
physiological (middle bars) and drug-dependent parameters (bottom bars). The larger a bar, the stronger
the impact of the varied parameter on the respective PK readout.
Discussion
The pulmonary pharmacokinetics of orally inhaled drugs are highly complex as pulmonary deposition, pul-
monary dissolution, mucociliary clearance, and pulmonary absorption create a complex interplay. Conse-
quently, defining adequate optimization parameters for orally inhaled drugs remains challenging. To ade-
quately capture and mechanistically predict the complex interplay of all pulmonary PK processes and to
identify optimization parameters, a PDE-based mechanistic PK framework was developed.
To build sufficient trust into a pulmonary PK model to use it for identification of optimal compound
characteristics, an adequate and systematic model evaluation is a prerequisite. However, previous mechanistic
modeling attempts, most noticeably the ones by Caniga et al. [56] and Boger et al. [20], lack such a thorough
evaluation. Indeed, the approach by Caniga et al., differentiating between airways and alveolar space albeit
less mechanistically than in the here-presented model, was evaluated for inhaled mometasone [56] and more
recently for additional fast dissolving drugs (formoterol, salbutamol, and budesonide) [57]. However, these
drugs would not provide the same insights into the pulmonary interplay of deposition, mucociliary clearance,
and dissolution as the slowly dissolving drug fluticasone propionate. An adequate prediction quality for
healthy and diseased populations, different particle sizes, slowly dissolving drugs or even insoluble particles
remains to be demonstrated.
A PDE model published by Boger et al. mechanistically included all pulmonary PK processes [20]. How-
ever, this model was based on a hypothetical drug, and while most of the characteristics of this hypothetical
drug can be considered reasonable, such as a Kp,lung of 4.9 or the oral bioavailability of 20%, other char-
acteristics such as a molecular weight of 250 Da were not considered typical for inhaled drugs (a typical
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molecular weight for an inhaled drug was reported to be ≈370 Da [58]). More importantly, since a model
evaluation based on a hypothetical drug is not feasible, no assessment of the model’s predictive capacities
was made.
Therefore, the here-presented model represents –to the best of our knowledge– the first systematically
evaluated and publicly available mechanistic pulmonary PK model. First, to evaluate the mechanistic
implementation of the mucociliary clearance, model-based lung retention profiles were compared to the
pulmonary retention of insoluble gold and polystyrene particles. 24 h particle retention was adequately
predicted, whereas long-term retention was underpredicted. One potential explanation could be that the
assumed inhaled volume was larger than described, resulting in more particle deposition in the alveolar
space. As the inhaled volume was defined based on the described experimental setup and not measured in
the study, a deviation from the assumption is possible. Since drug deposited in the alveolar space is not
cleared by the mucociliary clearance, this would result in higher long-term lung retention than predicted.
This explanation is reasonable due to high overall high (inter-subject) variability in pulmonary deposition
[59]. As pulmonary drug retention over 10 days should not be relevant for orally inhaled drugs, however,
this discrepancy was considered acceptable.
Second, to evaluate the mechanistic implementation of the interplay of particle deposition, mucociliary
clearance, and pulmonary drug dissolution, the PK of fluticasone propionate for different monodisperse
particles (1.5, 3, and 6 µm aerodynamic diameter) were predicted and compared to published data [38]. It
has to be stated that the reported absolute exposure metrics could not be reproduced. However, they appear
extraordinarily high and could not be reached even if the provided dose had been administered intravenously.
Nevertheless, the publication by Usmani et al. contains a unique data set, and therefore we still considered
the dataset, but by comparing the relative, not absolute, differences between the predictions for different
particle sizes. Based on this evaluation, we considered the model-based predictions for the varying particle
size effect as good.
Third, the modeling framework was used (without estimating additional input parameters) to simultane-
ously predict the PK of both fluticasone propionate and budesonide. For both drugs, plasma concentration-
time profiles in healthy volunteers were very well predicted. In addition, the difference in pharmacokinetics
between healthy volunteers and asthmatic patients was well predicted for fluticasone propionate. In contrast,
the impact of disease on the PK of budesonide was overpredicted, i.e. in asthmatic patients more drug was
predicted to be cleared by mucociliary clearance before it could be absorbed. This can be attributed to the
strongly increased deposition of drug particles in the first airway generations (see S2 Fig), a prediction based
on the assumption that the deposition probability across all airway generations is increased to a similar
extent by local airway obstructions. In contrast, it was discussed that airway obstructions in asthma are
located more peripherally in the conducting airways (in higher airway generations) [60] and therefore the
deposition would increase in more peripheral conducting airways rather than in the trachea and first airway
generations (as can be seen in the imaging data in [25]). Unfortunately, we are not aware of quantitative
data or deposition models based on such data, which would allow to better account for these differences
between healthy volunteers and asthmatic patients. Therefore, we were unable to integrate a more adequate
representation into our mechanistic model.
Based on the overall good agreement between the predictions and observed clinical data, we consider the
here-published PDE-based PK model as the currently best-evaluated mechanistic model for orally inhaled
drugs. However, even this mechanistic PK model still represents a simplification of reality and only includes
the above-mentioned pulmonary PK processes; macrophage clearance as well as pulmonary metabolism were
assumed not relevant. For some specific inhaled drugs, this assumption might not hold true. For example,
pulmonary metabolism was discussed to be of importance for inhaled macromolecules (e.g., insulin [61, 62]).
Macrophage clearance from the alveolar space to the conducting airways was characterized by a very long
half-life of 35 – 115 days [63, 64]. Consequently, compared to pulmonary absorption and dissolution kinetics
of most inhaled drugs, macrophage clearance is expected to be negligible. Furthermore, the considerable
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between-study variability in reported data has to be kept in mind when judging the model evaluation
accuracy. To recognize all of these assumptions, to understand their potential impact on the pulmonary PK,
and finally to adequately apply the here presented model framework, a sound understanding of respiratory
drug delivery remains essential.
As a last step of the presented analysis, we investigated the most relevant optimization parameters for
orally inhaled drugs. To this end, we performed a model-based sensitivity analysis to identify the most
impactful model parameters on pulmonary exposure metrics. The pulmonary AUC was considered as a
surrogate for pulmonary efficacy and the average concentration in the conducting airways after 24 h was
considered a surrogate for the effect duration of an inhaled drug. Finally yet importantly, the ratio between
pulmonary and systemic exposure was considered as a surrogate for lung selectivity of an inhaled drug (i.e.
the larger the ratio, the better the lung selectivity).
An impactful formulation-dependent model parameter was the particle size distribution of the inhaled
fluticasone propionate formulation. This might not be surprising as the particle size simultaneously affects
various pulmonary PK processes, i.e., larger particles deposit more centrally, dissolve slower and therefore a
higher fraction of drug would be cleared by the mucociliary clearance. As a result, model-based predictions
for larger particles indicated less lung exposure, shorter drug residence times in the lung, as well as a lower
lung selectivity. In contrast, smaller fluticasone propionate particles would improve all exposure metrics.
In conclusion, the model-based prediction framework indicates that reducing the particle size for inhaled
fluticasone propionate would be a reasonable optimization parameter. However, this optimization parameter
was predicted relevant only for fluticasone propionate. In contrast, the sensitivity analysis predicted no
relevant impact of the particle size to be expected for a drug like budesonide.
Impactful drug-specific optimization parameters for both drugs were (i) the lung partition coefficient, (ii)
the systemic clearance, and (iii) the dissolution rate. An increase in the pulmonary partition coefficient, which
indicates an increase in the pulmonary tissue affinity, was already previously suggested as an optimization
parameter for lung selectivity [65, 17, 66]. This parameter however has to be considered carefully as a high
tissue affinity / binding also would decrease the free pulmonary concentration. The systemic clearance had
low impact on the pulmonary drug concentrations, but a higher systemic clearance provided a better lung
selectivity. Therefore, especially for drugs with a critical systemic safety profile increasing the systemic
clearance can be considered meaningful. In agreement, the relevance of a high systemic clearance to reduce
systemic adverse effects for orally inhaled drugs was previously discussed [17, 67]. The pulmonary dissolution
rate for fluticasone propionate already seems to be nearly optimal to achieve a long-lasting efficacy, which
would be a good property for a once-daily administered drug. An additional decrease in the dissolution
kinetics was predicted to rather decrease the long-lasting efficacy. This finding is in agreement with recent
observations that increasing the tissue affinity might be a better strategy to prolong the efficacy than slow
dissolution [68]. Interestingly, while the dissolution rate constant can still be considered an optimization
criterion, the solubility in the airway lining fluid was not impactful for fluticasone propionate. This underlines
that actually the dissolution rate and not the solubility is important for pulmonary drug administration.
For budesonide, which is characterized by faster dissolution kinetics compared to fluticasone propionate,
the solubility was as important as the dissolution rate constant. The reason is that for budesonide, four
parameters simultaneously increased local drug concentrations in the epithelial lining fluids: (i) a higher
inhaled dose compared to fluticasone propionate, (ii) a higher fraction of the drug deposited in the lungs,
(iii) a lower permeability of budesonide resulting in a higher residence time of dissolved drug, as well as (iv)
a faster dissolution, which leads to more dissolved drug in the lining fluids.
Even though this sensitivity analysis provides good insights into potential optimization parameters, it has
to be recognized that varying a single input parameter at a time might not always be realistic. For example, a
higher lipophilicity would result in slower dissolution kinetics, higher permeability, and higher tissue affinity.
Therefore, as an extension of the here presented sensitivity analysis, a multi-parameter investigation might
be meaningful during compound optimization. Alternatively, the model-based evaluation allows comparing
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completely different drugs in a drug optimization program to select the best drug candidate. However, here
we evaluated the impact of the input parameters on the exposure in the conducting airways. These exposure
metrics only represent surrogate parameter and have to be carefully selected based on the mode of action
and the target location, i.e., for a target that would be located in the alveolar space other exposure metrics
should be considered relevant for a sensitivity analysis.
In addition to identifying optimization parameters, this sensitivity analysis allows addressing a second
aspect, namely to identify the most impactful (physiological) model parameters which have to be under-
stood to adequately predict the PK after oral inhalation. Vice versa, not knowing the exact values of less
impactful (physiological) parameters is less critical to predict the drug exposure in human. The most im-
pactful physiological parameters were tissue volume, perfusion, and mucociliary clearance. Less important
physiological parameters were, for example, fluid volume or surface area. An additional highly uncertain
parameter was the more central deposition pattern for asthmatic patients (these were corrected with an
empirical correction factor). Therefore, to improve the PK predictions for patients, it would be valuable
to generate and implement quantitative lung imaging data in patients [69]. Another important uncertainty
was the dissolution rate constant in the mucus. To our knowledge, no head-to-head comparison is available
for in vivo relevant dissolution assays for both dissolution in the mucus and the alveolar lining fluids. This
was why we had to make an assumption, namely a fivefold slower dissolution in the conducting airways
compared to the alveolar lining fluid. The reason for these adapted dissolution rate constants is that the
epithelial lining fluid in the conducting airways –the mucus– contains a lower concentration of surfactants,
which facilitate dissolution [70], compared to the alveolar lining fluid. In addition, the upper layer of the
mucus is characterized by a higher viscosity [71], which can also lead to a slower dissolution in comparison
to the alveolar space. However, even though this assumption described the data well, it should be verified
with in vitro dissolution experiments. In contrast, other uncertain (physiological) input parameters, such as
the volume of the lung lining fluids, were not impactful and therefore could be considered less critical.
The previously mentioned data-based limitations also represent the main opportunities to improve the
mechanistic PK model. First, it would significantly improve the applicability of the PK model framework
if an adequate pulmonary deposition model for asthmatics was also implemented (and later also for e.g.,
idiopathic pulmonary fibrosis). Furthermore, a more mechanistic representation of tissue distribution (e.g.,
separating extra- vs. intracellular concentrations) might increase the predictive power for drugs with a
high pulmonary tissue binding. Adapting the model to clinical PK data (e.g., by estimating parameters)
might improve the description of clinical data, but this would normally not be feasible during compound
optimization. Therefore, no pulmonary PK parameters were estimated in this work.
In conclusion, a PDE-based fully mechanistic pulmonary PK model was developed to perform model-
based predictions of the pulmonary and systemic pharmacokinetics of orally inhaled drugs based on in vitro,
formulation-specific, drug-specific, as well as physiological data. To our knowledge, this model is the first
fully mechanistic and systematically evaluated pulmonary PK model. We also have shown that due to a large
inter-study variability, model evaluation based on single (clinical) studies should be considered cautiously.
This evaluated PK framework was applied to provide unique insights into optimization criteria for orally
inhaled drugs by applying a model-based sensitivity analysis. It also provided insights which uncertainties
of the modeling framework still can be improved. Overall, our analysis demonstrated that the model-based
framework offers the potential to increase the quantitative understanding about inhaled drugs and ultimately,
the model-based approach is applicable to optimizing drugs and formulations for inhalation therapy.
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1 Derivation of the PDE model
1.1 Derivation of the dissolution model
The Noyes-Whitney equation [1] describes the dissolution flux dWdt in terms of properties of the dissolving
particles and the dissolution medium,
dW
dt
= −D · SA
h
(Cs − Cflu), (1)
where D is particle diffusivity, SA particle surface area, h height of the diffusion layer, Cs particle solubility
and Cflu concentration of dissolved substance in the medium.
Through geometric assumptions on particles, this equation can be turned into a differential equation
describing the change of volume of a dissolving particle. We assume particles to be spherical in shape, with
radius r, surface area SA = 4pir2, volume s = · 43pir3 and mass W = ρs. Furthermore, as suggested previously
[2], we assume the height of the diffusion layer to equate particle radius, h ≈ r.
Since parametrizing the model in terms of radius r leads to a singularity of the dissolution model when
r ↘ 0, in contrast to [2] we choose particle volume s = · 43pir3 as a size descriptor instead of particle radius.
Differentiating the particle mass equation,
dW
dt
(t) = ρ
ds
dt
(t), (2)
and equating Eqs. (1) and (2) yields
ds
dt
(t) = −D · 4pir(t)
2
ρ r(t)
(Cs − Cflu) = −D · 4pir(t)
ρ
(Cs − Cflu) = −
D · 4pi
(
s(t)
4
3pi
)1/3
ρ
(Cs − Cflu).
We opt to parametrize the dissolution model in terms of maximum dissolution rate kdiss = D ·Cs rather than
diffusivity D, since dissolution rate can be identified more directly from in vitro experiments (see Section
Evaluation of dissolution model against in vitro data). The resulting dissolution model reads
d(s, Cflu) =
4pi kdiss
( 43pi)
1/3 ρ
·
(
1− Cflu
Cs
)
· s1/3, ds
dt
(t) = −d(s(t), Cflu).
The concentration of dissolved substance, Cflu, also changes during dissolution. These processes are coupled
in the PDE model described below.
1.2 Derivation of the mucociliary clearance model
As explained in the main text, a continuous representation of airway radius r(x) depending on location x
within the conducting airways is derived by interpolation. Using the Hofmann/Sturm model
v = 0.12553
cm
min
·
(
d
1 cm
)2.808
,
we obtain a location-dependent mucociliary clearance model for a particle at location x(t) at time t:
dx
dt
(t) = −λmc
(
x(t)
)
= 0.12553
cm
min
·
[
2rbr
(
x(t)
1 cm
)]2.808
= −0.8791 cm
min
· rbr
(
x(t)
1 cm
)2.808
.
2
1.3 Individual and population states
Physiologically-structured models describe the time evolution of a set of individuals/particles, each exhaus-
tively described by a vector of characteristics called state, denoted z, and which changes over time. The time
evolution of the state of any individual is assumed to be governed by a law G, i.e.
dz
dt
(t) = G(t, z(t)), z(0) = z0.
Assuming that a population consists of a large number of individuals, it is natural not to describe each
single individual but rather the time evolution of a density ρ(t, z) of individuals over the state space. In this
representation, the total number of particles is given by
N(t) =
∫
ρ(t, z)dz,
and the number of particles within a particular subregion ω of the state space is given by
Nω(t) =
∫
ω
ρ(t, z)dz.
For such a domain ω, we set ω(t) = {z(t) : z0 ∈ ω}. Assuming that the number of individuals is conserved
in the state space, we obtain
d
dt
Nω(t)(t) ≡ 0
as long as ω(t) does not touch the state space boundary. From this expression, a so-called continuity equation
can be derived (see [3]):
∂tρ(t, z) + divz
[
G(t, z)ρ(t, z)
]
= 0. (3)
1.4 Derivation of physiologically-structured population models (PSPMs)
In our application context, the population consists of inhaled undissolved drug particles of different sizes,
deposited at different locations within the conducting airways or within the alveolar space. The number of
particles can only change if particles are (i) cleared to the GI tract by the mucociliary elevator (mucociliary
clearance beyond the trachea, x(t) = 0) or (ii) completely dissolved (s(t) = 0).
1.4.1 Conducting airways
The particle state z = (x, s) ∈ [0, xTB]× [0, smax] can change by mucociliary clearance or dissolution (illus-
trated in Fig 1): (
dx
dt (t)
ds
dt (t)
)
=
( −λmcc(x(t))
−d(s(t), Cbrflu(x(t), t))
)
︸ ︷︷ ︸
=:Gbr(t,x(t),s(t))
,
and Eq. (3) yields the location- and size-structured bronchial PSPM
∂tρ
br(t, x, s)− ∂x
[
λmcc(x)ρ
br(t, x, s)
]
− ∂s
[
d
(
s, Cbrflu(t, x)
)
ρbr(t, x, s)
]
= 0. (4)
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Figure 1: Phase plane representation of a drug particle in the conducting airways. Each particle is charac-
terized by its location and size. Over time, particles move within this two-coordinate system until they are
either cleared to the GI tract or completely dissolved.
1.4.2 Alveolar space
Since mucociliary clearance is not present in the alveolar space, the particle state z = s ∈ [0, smax] can
change by dissolution only:
ds
dt
(t) = −d(s(t), Calvflu (t))︸ ︷︷ ︸
=:Galv(t,s(t))
,
and Eq. (3) yields the size-structured alveolar PSPM
∂tρ
alv(t, s)− ∂s
[
d
(
s, Calvflu (t)
)
ρalv(t, s)
]
= 0.
1.5 Mass balances
When coupling the PSPM models to equations for dissolved drug in lining fluids, the number of molecules
(not particles) have to be conserved during dissolution and mucociliary clearance. This model feature is
ensured by deriving dissolution and mucociliary clearance rates directly from the PSPMs, which is shown in
the following. The number of undissolved molecules in the conducting airways / the alveolar space are given
by
Abrsol(t) =
xTB∫
0
smax∫
0
sρbr(t, x, s)dxds, Aalvsol (t) =
smax∫
0
sρalv(t, s)ds.
We illustrate the derivation for the conducting airways, using integration by parts at step (∗):
4
dAbrsol
dt
(t) =
xTB∫
0
smax∫
0
s∂tρ
br(t, x, s)dxds
(4)
= −
xTB∫
0
smax∫
0
s
(
− ∂x[λmcc(x)ρbr(t, x, s)]− ∂s[d(s, Cbrflu(t, x))ρbr(t, x, s)]
)
dxds
(∗)
=
smax∫
0
s
(
λmcc(xTB) ρ
br(t, xTB, s)︸ ︷︷ ︸
=0 (no inflow)
−λmcc(0)ρbr(t, 0, s)
)
ds
−
xTB∫
0
smax∫
0
d
(
s, Cbrflu(t, x)
)
ρbr(t, x, s)dxds+
xTB∫
0
smaxd
(
smax, C
br
flu(t, x)
)
ρbr(t, x, smax)︸ ︷︷ ︸
=0 (no inflow)
dx
= −
smax∫
0
s λmcc(0)ρ
br(t, 0, s)ds
︸ ︷︷ ︸
cleared by mucociliary elevator
−
xTB∫
0
smax∫
0
d
(
s, Cbrflu(t, x)
)
ρbr(t, x, s)dxds
︸ ︷︷ ︸
dissolved into lining fluids
A similar but simplified reasoning applies to the alveolar space, where only dissolution, not mucociliary
clearance, needs to be considered.
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2 Numerical resolution of the PDE model
2.1 Notation
We consider a uniform time discretization step ∆t > 0, a location discretization
0 = x1/2 < ... < xK+1/2 = xTB
and a size discretisation
0 = s1/2 < ... < sL+1/2 = smax
These discretization points are understood as vertices of mesh elements (k, l) = [xk−1/2, xk+1/2] ×
[sl−1/2, sl+1/2] within which unknowns (approximations of ρbr, Cbrflu, etc.) are defined; they appear in the
discretization of the location- and size-structured model in the conducting airways. The same size grid is also
used when discretizing the size-structured model in the alveolar space. Furthermore, we define the center
(xk, sl) of mesh element (k, l) from the above discretization points,
xk :=
xk−1/2 + xk+1/2
2
, k ∈ {1, ..,K},
sl :=
sl−1/2 + sl+1/2
2
, l ∈ {1, .., L}.
We use the following notation:
• ∆xk := xk+1/2 − xk−1/2 (location length of mesh element (k, ·))
• ∆sl := sl+1/2 − sl−1/2 (size length of mesh element (·, l)); we also define ∆sl+1/2 := sl+1 − sl (this
expression will appear later during computations)
• Abbreviations for location-structured physiology in conducting airways: λk := λmc(xk), rbrk := rbr(xk),
qbrk := q
br(xk), a
br
flu,k := a
br
flu(xk), a
br
tis,k := a
br
tis(xk)
• ρbr,nk,l as the numerical approximation of ρbr(tn, xk, sl)
• ρalv,nl as the numerical approximation of ρalv(tn, sl)
• Cbr,nflu,k as the numerical approximation of Cbrflu(tn, xk)
• Cbr,ntis,k as the numerical approximation of Cbrtis(tn, xk)
• Calv,nflu as the numerical approximation of Calvflu (tn)
• Calv,ntis as the numerical approximation of Calvtis (tn)
• Ay,nx as the numerical approximation of Ayx(tn) (total amount of drug in a certain state; one of Abrsol,
Abrflu, A
br
tis, A
alv
sol , A
alv
flu , A
alv
tis , A
clear
mcc , A
clear
sys , A
sys
tot), with ’sol’ meaning ’solid’, i.e. undissolved.
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2.2 Upwind discretization of physiologically-structured population equations
Upwind discretizations, i.e. non-centered finite difference approximations depending on the flow direction,
are well tailored to PSPMs, resulting in stable discretizations as long as the timestep ∆t is small enough
(called a CFL condition).
The upwind discretization of the conducting airway PSPM
∂tρ
br(t, x, s)− ∂x
[
λmc(x)ρ
br(t, x, s)
]− ∂s[d(s, Cbrflu(t, x))ρbr(t, x, s)] = 0
is given by
ρbr,n+1k,l − ρbr,nk,l
∆t
− λk+1/2ρ
br,n
k+1,l − λk−1/2ρbr,nk,l
∆xk
− d(sl+1/2, C
br,n
flu,k)ρ
br,n
k,l+1 − d(sl−1/2, Cbr,nflu,k)ρbr,nk,l
∆sl
= 0,
for n ∈ {1, ..., N}, k ∈ {1, ...,K}, l ∈ {1, ..., L} (with ρbr,nK+1,l = ρbr,nk,L+1 = 0, i.e. no inflow condition). Similarly
the upwind discretization of the alveolar PSPM
∂ρalv(t, s)− ∂s
[
d(s, Calvflu (t))ρ
alv(t, s)
]
= 0
is given by
ρalv,n+1l − ρalv,nl
∆t
− d(sl+1/2, C
alv,n
flu )ρ
alv,n
l+1 − d(sl−1/2, Calv,nflu )ρalv,nl
∆sl
= 0.
Within this framework, the number of undissolved drug molecules is approximated by
Abr,nsol,k :=
L∑
l=1
∆slslρ
br,n
k,l (location k in conducting airways),
Aalv,nsol :=
L∑
l=1
∆slslρ
alv,n
l (alveolar space).
2.3 Implicit discretization of linear processes
Recognizing that all processes except for dissolution and mucociliary clearance are linear, we propose an
implicit discretization to ensure unconditional stability of these other processes, too. The numerical scheme
is formulated in terms of local amounts (in bronchial/alveolar fluid/tissue) rather than concentrations. To
this end, we define
V brflu,k := ∆xk a
br
flu,k (lining fluid volume at k-th location grid cell)
V brtis,k := ∆xk a
br
tis,k (tissue volume at k-th location grid cell)
and obtain the amounts
Abr,nflu,k := C
br,n
flu,kV
br
flu,k, A
br,n
tis,k := C
br,n
tis,kV
br
tis,k (conducting airways),
Aalv,nflu := C
alv,n
flu V
alv
flu , A
alv,n
tis := C
alv,n
tis V
alv
tis (alveolar space).
Furthermore, it will be useful to define
PSbrk := ∆xk 2pir
br
k Papp (permeability-surface area product at k-th location grid cell)
Qbrk := ∆xk q
br
k (perfusion of k-th location grid cell).
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To arrive at a numerical scheme formulated on the computational grid, integrals are discretized as follows:∫ smax
0
f(s)ds ⇒
L∑
l=1
∆slf(sl),
∫ xTB
0
f(x)dx ⇒
K∑
k=1
∆xkf(xk)
Bronchial kinetics
Abr,n+1flu,k −Abr,nflu,k
∆t
= ∆xk
L∑
l=2
∆sl−1/2d(sl−1/2, C
br,n
flu,k)ρ
br,n
k,l︸ ︷︷ ︸
dissolved (see section below)
− PSbrk
(
Abr,n+1flu,k
V brflu,k
− A
br,n+1
tis,k
V brtis,kKpl,u
)
Abr,n+1tis,k −Abr,ntis,k
∆t
= PSbrk
(
Abr,n+1flu,k
V brflu,k
− A
br,n+1
tis,k
V brtis,kKpl,u
)
−Qbrk
(
Abr,n+1tis,k
V brtis,k
R
Kpl
− A
sys,n+1
ctr
V sysctr
)
Alveolar kinetics
Aalv,n+1flu −Aalv,nflu
∆t
=
L∑
l=2
∆sl−1/2d(sl−1/2, C
alv,n
flu )ρ
alv,n
l − PSalv
(
Aalv,n+1flu
V alvflu
− A
alv,n+1
tis
V alvtis Kpl,u
)
Aalv,n+1tis −Aalv,ntis
∆t
= PSalv
(
Aalv,n+1flu
V alvflu
− A
alv,n+1
tis
V alvtis Kpl,u
)
−Qalv
(
Aalv,n+1tis
V alvtis
R
Kpl
− A
sys,n+1
ctr
V sysctr
)
Systemic kinetics
Asys,n+1gut −Asys,ngut
∆t
=
L∑
l=1
∆slslλ1/2ρ
br,n
1,l︸ ︷︷ ︸
mucociliary clearance (see section below)
−k01Asys,n+1gut
Asys,n+1ctr −Asys,nctr
∆t
= Fk01A
sys,n+1
gut − k12Asys,n+1ctr + k21Asys,n+1per
+Qalv
(
Aalv,n+1tis
V alvtis
R
Kpl
− A
sys,n+1
ctr
V sysctr
)
+
K∑
k=1
Qbrk
(
Abr,n+1tis,k
V brtis,k
R
Kpl
− A
sys,n+1
ctr
V sysctr
)
Asys,n+1per −Asys,nper
∆t
= k12A
sys,n+1
ctr − k21Asys,n+1per
An+1clear −Anclear
∆t
= (1− F )k01Asys,n+1gut + k10Asys,n+1ctr
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2.4 Mass conservation of PDE discretisation
The above terms are chosen such that the number of molecules is conserved, i.e., the total amount of drug
in the body plus the amount excreted, given by
Antot = A
br,n
sol +
K∑
k=1
(
Abr,nflu,k +A
br,n
tis,k
)
︸ ︷︷ ︸
in conducting airways
+Aalv,nsol +A
alv,n
flu +A
alv,n
tis︸ ︷︷ ︸
in alveolar space
+ Asys,nctr +A
sys,n
per +A
sys,n
gut +A
n
clear︸ ︷︷ ︸
in GI tract, systemic circulation or excreted
,
remains constant for all n. Mass conservation during uptake from lining fluid to lung tissue can be seen
directly from the rates in the equations: the same terms, e.g.
PSbrk
(
Abr,n+1flu,k
V brflu,k
− A
br,n+1
tis,k
V brtis,kKpl,u
)
,
appear in both equations with opposing signs (for systemic uptake from conducting airway tissue, contri-
butions at different locations are summed). Furthermore, using the upwind formulation, we can decompose
the rate of change of the amount of undissolved drug:
Abr,n+1sol −Abr,nsol
∆t
=
K∑
k=1
L∑
l=1
∆xk∆sl sl
ρbr,n+1k,l − ρbr,nk,l
∆t
= −
K∑
k=1
L∑
l=1
∆xk∆sl sl
(
−λk+1/2ρ
br,n
k+1,l − λk−1/2ρbr,nk,l
∆xk
− d(sl+1/2, C
br,n
flu,k)ρ
br,n
k,l+1 − d(sl−1/2, Cbr,nflu,k)ρbr,nk,l
∆sl
)
= +
K∑
k=1
L∑
l=1
∆sl sl
(
λk+1/2ρ
br,n
k+1,l − λk−1/2ρbr,nk,l
)
+
K∑
k=1
L∑
l=1
∆xksl
(
d(sl+1/2, C
br,n
flu,k)ρ
br,n
k,l+1 − d(sl−1/2, Cbr,nflu,k)ρbr,nk,l
)
= −
L∑
l=1
∆sl slλ1/2ρ
br,n
1,l︸ ︷︷ ︸
mucociliary clearance
−
K∑
k=1
∆xk
L∑
l=2
∆sl−1/2d(sl−1/2, C
br,n
flu,k)ρ
br,n
k,l︸ ︷︷ ︸
dissolution at location k
and noting that these two terms are matched in the equations for dissolved drug in the lining fluid and
of cleared drug, we can conclude that mass is conserved during dissolution and mucociliary clearance. An
analogous computation shows mass conservation during dissolution in the alveolar space. Mass balance was
checked systematically during all simulations shown.
2.5 Projections onto the computational grid
Deposition patterns, as well as several parameters used in the PSPMs, are not resolved at the same scale
as the computational grid. Therefore, a projection step is necessary prior to being able to integrate these
quantities into the model.
2.5.1 Deposition patterns
Deposition data are given for each airway generation g1, ..., gK and for a fixed set of reference particle sizes
S1, ..., SL, resulting in a discrete deposition pattern (Dk,l). The dose should be conserved, equivalent to
conservation of number of molecules, but not number of particles.
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We proceeded as follows (see Fig. 2 for an illustration):
• We define a region Sεk around Sk, given bySεk = [Sk − ε, Sk + ε], with small ε such that all such regions
are disjoint.
• From the discrete values Dk,l, we define a continuous function
D(x, s) =
∑
k,l
1
2ε|gk|1{x∈gk,s∈[Sk−ε,Sk+ε]},
such that
∫
gk×Sεk D(x, s)dxds = Dk,l.
• We define the initial condition on the computational grid by
ρ0k,l =
1
∆xk ∆sl
∫
C(k,l)
D(x, s)dxds
for grid cell C(k, l) =
[
xk− 12 , xk+ 12
]× [sl− 12 , sl+ 12 ]
2.5.2 Per-generation parameters
For a per-generation parameter (e.g., airway radius, blood flow, ...), generically denoted P , we construct a
location-resolved representation using the previous construction only in the location coordinate, i.e.:
• From the discrete values Pk, we define a continuous function
P (x) =
∑
k
1
|gk|1{x∈gk},
such that
∫
gk
P (x)dx = Pk.
• We define the location-resolved representation on the computational grid by
pk =
1
∆xk
x
k+1
2∫
x
k− 1
2
P (x)dx.
3 Additional model evaluations
3.1 Evaluation of dissolution model against in vitro data
We evaluated the dissolution model against in vitro data from a dissolution study [4], where the authors
evaluated the dissolution kinetics of fluticasone propionate and budesonide particles with defined particle
sizes (see Table 1).
Based on the in vitro data, we compared different dissolution models:
• a first-order dissolution model (estimated empirically; size-independent)
• an unsaturable dissolution model (formally corresponding to Cs = +∞ in the dissolution model)
• saturable dissolution models with different solubilities
The results are shown in Fig. 3. A particle size-dependency is clearly visible, as well as a saturation effect.
Among the different saturable dissolution models, the parametrization using in house data resulted in a
qualitatively better description than the values reported in [4].
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Figure 2: Resolution of data against computational grid. Deposited amounts of particles with a particular
size and at a particular airway location (black dots) are first distributed evenly within the respective airway
generation and a small size range (blue rectangles), yielding a continuous representation of deposition within
state space. The numerical approximation to the location- and size-structured density is defined on an
independent computational grid. Its initial value within a grid cell is the average of the values of the
continuous representation. Contributing location-size regions to a particular grid cell are highlighted in gray.
3.2 Representation of lining fluid height in conducting airways based on liter-
ature data
Different values for the thickness of the lining fluid layer in the conducting airways have been reported. After
reviewing the literature, we concluded that the linear relationship shown in Fig. 4 adequately described the
current state of knowledge.
We decided not use literature values on total lung lining fluid volume since the reported values are
not experimentally measured values but rather estimates based on height measurements and geometrical
considerations. However, we note that the total lining fluid volume computed under the our geometrical
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Substance ACI stage Cutoff size range Aerodyn. diam. Geometric diam.
Fluticasone propionate 4 2.1 – 3.3 µm 2.7 µm 3.2 µm
Fluticasone propionate 2 4.7 – 5.8 µm 5.25 µm 6.2 µm
Budesonide 4 2.1 – 3.3 µm 2.7 µm 2.4 µm
Table 1: Aerodynamic and geometric particle sizes corresponding to the experimental protocols of [4].
Particles within defined ranges of aerodynamic particle sizes were obtained from different stages of Anderson
cascade impactors (ACI). For simulation of dissolution kinetics, we took the geometric diameter correspond-
ing to the mean aerodynamic particle diameter within each impactor stage.
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Figure 3: Comparison of dissolution models based on in vitro dissolution data.
assumptions (≈ 1.2 mL) was smaller than the ones given in the literature (10–70 mL).
3.3 Evaluation of Usmani data
As stated in the main text, we could not reproduce the fluticasone propionate exposure indices reported by
Usmani et al. [9] based on the provided study information. Here we provide full details for this statement.
For the smallest particles of 1.5 µm diameter, Usmani et al. reported an AUC0-12h of 923.28 pg · h/mL, i.e.
in molar units 1.84 nM ·h. Assuming 100 % lung uptake, no mucociliary clearance and a full systemic uptake
within 12 h, and taking the literature value for fluticasone propionate clearance of 73 L/h [10], we obtain a
very conservative upper bound of AUCmax =
Dose
CL·MW = 1.37 nM · h.
A more realistic, albeit still conservative calculation and a simulation with the PDE model are shown
in Table 2. In conclusion, the reported AUC value is approximately 2-4 times larger than what could be
reasonably expected. Accordingly, Cmax values are also much higher than predicted by the PDE model.
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Figure 4: Model for height of location-resolved lining fluid (solid black line) compared to reported literature
data [5, 6, 7, 8].
4 Simulation of pulmonary deposition patterns
4.1 Settings in MPPD software
In order to predict the pulmonary deposition patterns, the MPPD software v2.1 was used [11]. This software
allows to predict the generation-dependent pulmonary deposition of inhaled particles, where generations 1-17
represent the conducting airways (generation 1 = trachea) and generations 18-25 the alveolar space. Three
types of input data are required in the MPPD software: (1) airway morphometry, (2) particle properties, and
(3) exposure condition, as outlined below. The MPPD software was only applied to simulate the deposition
patterns but not used to investigate the clearance of particles from the lung.
Airway morphometry. For all predictions performed with the MPPD software, the airway morphometry
was represented by the human “Yeh/Schum 5-Lobe” model [12]. The inhalation flow characteristics
were assumed to be represented by uniform expansion of the lung so that consequently also the inhala-
tion and exhalation flow were constant over time. The standard airway morphometry defined in the
MPPD software was selected for all deposition pattern predictions, i.e. the default values for functional
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Assumptions for AUC calculation Calculated AUC
Lung dose MCC Timespan (compared to reported AUC)
100% no AUC0-∞ 26% lower than reported
56% no AUC0-∞ 58% lower than reported
56% yes AUC0-12h 74% lower than reported
Table 2: Comparison of calculated AUC vs. reported AUC0-12h for different assumptions. Even under the
most conservative assumptions, AUC is considerably underestimated, which becomes more pronounced as
the model gets more realistic.
residual capacity (3300 mL) and upper respiratory tract volume (50 mL) were used [13].
Particle properties. The inhaled particle properties were defined based on the information in the re-
spective publications, or alternatively for the respective inhalation device (references are provided in
Table 3). For all predictions, the density of the particles was set to 1 g/cm3; and the particle diameter
was defined as the mass median aerodynamic diameter, which is typically provided in literature. As
described in the main manuscript, the difference between aerodynamic and geometric diameters was
accounted for, such that the real surface area could be used as an input parameter to the dissolution
model. The MPPD software was only used to predict pulmonary deposition patterns of monodis-
perse particles. To predict the deposition patterns for the monodisperse gold/polystyrene particles
(Study I) and the inhaled monodisperse fluticasone propionate particles (Study II), this information
was sufficient. Whenever pulmonary deposition patterns of a particle size distribution were required
(Studies III/IV), these were generated in a two-step approach. First, all relevant monodisperse parti-
cles size bins of the particle size distribution were simulated as monodisperse particles with the MPPD
software. In a second step, the complete deposition pattern was calculated by normalizing the de-
posited amount per particle size bin by the dose in this respective bin. The two additional options
of the MPPD software, namely the “Nanoparticle Model” and “Inhalability Adjustment” were not
applied to predict the deposition patterns.
Exposure conditions. The exposure scenario was set to constant exposure and the body orientation during
the inhalation process was assumed “upright”. Furthermore, for all predictions, it was assumed that
the breathing scenario was represented by oral breathing, which is the typical inhalation route for
drugs delivered to the lungs. Breathing frequency, tidal volume, inspiratory fraction as well as pause
fraction were all defined based on the inhalation flow properties provided in the respective publications
(see Table 3).
4.2 Adaptation of deposition patterns for asthmatic patients
Since the MPPD software predicts deposition patterns in healthy volunteers, it cannot directly be used to
predict deposition patterns in asthmatic or COPD patients. In these patients, due to narrowed airways,
deposition is more central in comparison to healthy volunteers. Whenever patients were considered in a
study rather than healthy volunteers, deposition patterns had to be adapted adequately. To this end, the
fraction of the inhaled dose deposited in any specific airway generation was increased by an adjustment
factor such that the deposited fraction of the lung dose in the alveolar space was 2-fold lower than in healthy
volunteers. This number was derived from published data on conducting airway to alveolar deposition ratios
[17].
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Study I Study II Study III Study IV
Particle properties
Substance
gold /
polystyrene
fluticasone
propionate
fluticasone
propionate
budesonide
Formulation type monodisperse monodisperse polydisperse polydisperse
Particle size(s) 5µm diameter
1.5 / 3 / 6 µm
diameter
distribution
based on [14]
distribution
based on [14]
Exposure scenario
Device
custom setup
(see [15])
Inhalation
chamber
Diskus R© Turbohaler R©
Breathing frequency 6/min 5/min 6/min 6/min
Tidal volume 200 mL 2000 mL 2000 mL 2000 mL
Inhalation time 1 sec 4 sec 1.33 sec 1.33 sec
Exhalation time 1 sec 3 sec 2.67 sec 2.67 sec
Pause time 8 sec 5 sec 6 sec 6 sec
Inhalation flow 12 L/min 30 L/min 90 L/min 60 L/min
Deposition pattern
corrections
Lung dose no correction
56.3% / 51% /
46.0%
14.5% based on
[16]
35% based on
[16]
Central/peripheral
deposition ratio
no correction
central
deposited
fraction: 56.1%
/ 65.7% / 75.4%
2-fold lower
alveolar
deposition for
asthma patients
[17]
2-fold lower
alveolar
deposition for
asthma patients
[17]
Table 3: Study-specific input data to the MPPD software.
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5 Generation of in-house data
5.1 In vitro solubility determination in surfactant containing medium
For in vivo relevant characterization of the drug solubility, the surfactant-containing medium Alveofact R©,
a commercially available product, was taken. Alveofact R©contains phospholipids obtained from bovine lung
(i.e., surfactants) and is available as dry powder ampoules ready for reconstitution. As reconstitution
medium, a 0.1 mol/l sodium dihydrogenecarboante buffer with pH 7.4 was used. A suspension with 50
mg/ml Alveofact R©was produced according to the information and instruction for use of the commercial
product. At these concentrations, Alveofact R©forms a micellar system. 1 mg of drug (either budesonide or
fluticasone propionate) is suspended in 1 ml of this medium and shaken for 24 h at 37 ◦C. Afterwards, the
suspension is filtered with a commercially available Whatman Mini-UniPrep syringeless filter containing a
0.45 µm filter membrane out of glass microfibers. As the micelles pass this membrane and as the concentra-
tion of phospholipids is too high to be directly injected in the HPLC system for analysis of the solubilized
amount of drug, the micelles are destroyed by adding DMSO in a 1:1 ratio to the filtered micellar solution.
The phospholipids can be separated by an additional 5 – 10 minutes centrifugation step. A small aliquot of
the remaining solution is taken and injected into a HPLC system for quantitative analysis of the solubilized
amount of drug.
5.2 Blood to plasma ratio determination
To determine the Blood:Plasma (BP) ratio, the respective amount of the drug (i.e., fluticasone propionate)
was added to 490 µL human blood and to 490 µL plasma samples to obtain a drug concentration of 10 µM.
Both the plasma (plasma sample #2) and the blood samples were incubated with the drug for 15 minutes
at 37 ◦C (n=3). Afterwards the blood sample was centrifuged at 3000 rpm to separate the blood cells
from the plasma sample (plasma sample #1). The respective plasma concentrations were determined by
MS-based analysis. In a last step, the BP ratio was calculated by dividing the drug concentration in plasma
sample #2 by the drug concentration in plasma sample #1. To ensure quality of the measurement, the
degree of hemolysis was determined and considered negligible for all BP experiments. In addition, a control
experiment without any drug was performed in parallel to determine the hematocrit of all three samples.
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